Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the FDA’s attitude toward mRNA and COVID-19 vaccines that have investors ...

Prothena (PRTA – Research Report) received a Hold rating and price target from Oppenheimer analyst Jay Olson yesterday. The company’s shares closed last Friday at $6.58. Confi ...

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided busi ...

(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended ...

SALT LAKE CITY — Denali Therapeutics is advancing the fight against neurodegenerative diseases thanks to pioneering work in methods to carry medicines across the blood-brain barrier, a critical ...

AlphaQuest LLC increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 177.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC.

Analysts expect Denali Therapeutics to post earnings of ($0.75) per share and revenue of $12.75 million for the quarter. Denali Therapeutics Stock Down 3.9 % Shares of NASDAQ DNLI opened at $20.75 ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced key anticipated milestones for 2025 across its portfolio. Chief Executive ...

William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for neurodegenerative diseases. The analyst highlights that Denali is ...